An investigation on behalf of investors in Juno Therapeutics Inc (NASDAQ:JUNO) shares over potential wrongdoing at Juno Therapeutics was announced and NASDAQ:JUNO stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 05/05/2016 --An investigation for shareholders of Juno Therapeutics Inc (NASDAQ:JUNO) was announced over potential breaches of fiduciary duties by certain directors at Juno Therapeutics.

Investors who purchased shares of Juno Therapeutics Inc (NASDAQ:JUNO) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm concerns whether certain Juno Therapeutics Inc directors breached their fiduciary duties.

Juno Therapeutics Inc reported that its Net Loss increased from $243.41 million in 2014 to $239.38 million in 2015. Shares of Juno Therapeutics Inc (NASDAQ:JUNO) declined from $68.36 per share in June 2015 to as low as $22.37 per share on February 3, 2016.

On May 4, 2016, NASDAQ:JUNO shares closed at $38.30 per share.

Those who purchased shares of Juno Therapeutics Inc (NASDAQ:JUNO), have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com